Attorney Docket No. 3523 P 002   PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re U.S. Patent Application of:)
Wilhelm SCHWAEBLE & Robert Braidwood SIM   )
)
From: PCT/GB97/03275   28 November 1997   )
     British Appln. No. 9624731.7   28 November 1996   )
)
For: COMPLEMENT INHIBITOR   )
)

REQUEST FOR FILING A CONTINUATION OF AN INTERNATIONAL APPLICATION

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231   ATTN: BOX PATENT APPLICATION

Sir:

This is a request for filing a continuation application under 37 C.F.R. 1.53(b), of pending prior International Application No. PCT/GB97/03275, filed 28 November 1997 (claiming priority from British Appln. No. 9624731.7, filed 28 November 1996), titled COMPLEMENT INHIBITOR, which designated the United States.

Enclosed are the specification, claims and Abstract, along with 15 sheets of formal drawings (Figures 1-4).

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Small Entity		or	Other Than A Small Entity	
			Rate	Fee	or	Rate	Fee
Basic Fee				$380	or		
Total Claims	20 - 16 =	0	x 9 =	$0	or	x 18 =	
Indep. Claims	3 - 4 =	1	x 39 =	$39	or	x 78 =	
□ First Presentation of Multiple Dependent Claim			x130 =		or	x 260 =	
			Total	$419	or	Total	

Amend the specification by inserting before the first line the sentence: "This Application is a Continuation of International Application No. PCT/GB97/03275, filed 28 November 1997 (claiming priority from British Appln. No. 9624731.7, filed 28 November 1996), now pending (which is hereby incorporated by reference)."

⇨   Priority of foreign Application No.9624731.7 filed 28 November 1996 in Britain is claimed under

35 U.S.C. 119(a)-(d).

⇨   A Preliminary Amendment is enclosed.

        We also enclose for completeness:

- PCT application as published (without search report)

- International Search Report

- Notification of Transmittal of International Preliminary Examination Report

- Notification Concerning Submission of Priority Document

- Notice Informing Applicant of Communication of International Application to Designated Offices

- Information Concerning Elected Offices Notified of Their Election

- Notification of Receipt of Demand

                                        Respectfully submitted,

Date: May 21, 1999   By: Monique A. Morneault

                                        Monique A. Morneault   Reg. No. 37,893
                                        WALLENSTEIN & WAGNER, LTD.
                                        311 South Wacker Drive - 5300
                                        Chicago, IL   60606
                                        1-312-554-3300

:smf   74724

_____

Express Mail Label No. EL237761323US

Date of Deposit: MAY 21, 1999

I hereby certify that this paper or fee is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" service under
37 C.F.R. § 1.10 on the date indicated above and is addressed to:
ASSISTANT COMMISSIONER FOR PATENTS, Washington, D.C. 20231
(ATTN: BOX PATENT APPLICATIONS).

Susan M Franklin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re U.S. Patent Application of:)
Wilhelm SCHWAEBLE & Robert SIM   )
)
From: PCT/GB97/03275   28 November 1997   )
    British Appln. No. 9624731.7   28 November 1996   )
)
For: COMPLEMENT INHIBITOR   )

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231   ATTN: BOX PATENT APPLICATION

    Please amend the above-identified application as follows:

IN THE CLAIMS:

    Claim 3, delete the phrase "either one of claims 1 or 2" and insert -- claim 1 -- .

    Claim 7, delete the phrase "either one of claims 1 or 2" and insert -- claim 1 -- .

    Claim 9, delete the phrase "any one of claims 1-8" and insert -- claim 1 -- .

    Claim 11, delete the phrase "any one of the preceding claims" and insert -- claim 1 -- .

    Claim 12, late line, delete the phrase "any one of claims 1-10" and insert -- claim 1 -- .

    Claim 13, last line, delete the phrase "any one of claims 1-10" and insert -- claim 1 -- .

    Claim 16, last line, delete the phrase "any one of claims 1-10" and insert -- claim 1 -- .

    The above amendments are being submitted to place the claims in proper format. No new matter is being added through these amendments. Applicant respectfully requests entry of the above amendments.

Respectfully submitted,

Date: _May 21, 1999_

:smf   74315

By: _Monique A. Morneault_
    Monique A. Morneault   Reg. No. 37,893
    WALLENSTEIN & WAGNER, LTD.
    311 South Wacker Drive - 5300
    Chicago, IL   60606   1-312-554-3300

In re CONTINUATION application of: UNIVERSITY OF LEICESTER
Inventors: Wilhelm SCHWAEBLE and Robert Braidwood SIM

For: COMPLEMENT INHIBITOR

Our Docket No. 3523 P 002 (M96/0591/US)

THIS APPLICATION CLAIMS PRIORITY FROM PCT/GB97/03275 (FILED 28 NOVEMBER 1997) AND BRITISH APPLN. NO. 9624731.7 (FILED 28 NOVEMBER 1996)

ENCLOSED: POSTCARD

REQUEST FOR FILING A CONTINUATION OF AN INTERNATIONAL APPLICATION

34-PAGE PATENT APPLICATION

2-PAGE PRELIMINARY AMENDMENT

15 SHEETS OF <u>FORMAL</u> DRAWINGS (FIGURES 1-4)

PCT application as published (without search report)
International Search Report
Notification of Transmittal of International Preliminary Examination Report
Notification Concerning Submission of Priority Document
Notice Informing Applicant of Communication of International Application to Designated Offices
Information Concerning Elected Offices Notified of Their Election
Notification of Receipt of Demand

TO FOLLOW:

CHECK FOR FILING FEE

EXECUTED DECLARATION/POWER OF ATTORNEY

EXECUTED VERIFIED STATEMENT

CERTIFIED COPY OF PRIORITY APPLICATION

I HEREBY CERTIFY THAT THIS PAPER AND THE ABOVE DOCUMENTS ARE BEING DEPOSITED WITH THE U.S POSTAL SERVICE AS EXPRESS MAIL IN AN ENVELOPE ADDRESSED TO BOX PATENT APPLICATIONS, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON May 21, 1999 UNDER EXPRESS MAIL NO. EL237761323US.

PLEASE ADDRESS ALL FUTURE COMMUNICATIONS TO:

MONIQUE A. MORNEAULT, ESQ.
WALLENSTEIN & WAGNER
311 South Wacker Drive - 5300
Chicago, IL   60606
(312) 554-3300

74279

Complement Inhibitor

The present invention concerns regulation of complement activation, in particular the fluid phase regulation of complement activation.

The complement system (see McAleer, M.A. and Sim, R.B. in Activators and Inhibitors of Complement, Kluwer Academic Publishers, Dordrecht, ed R.B. Sim, 1993, p. 1-15; Reid, K.B.M. and Law, A., 1988, Complement, IRL Press, Oxford) is concerned with host defence against infection - upon activation of the system a catalytic set of reactions and interactions occur resulting in the targeting of the activating cell, organism or particle for destruction. Due to the destructive nature of the system it has the potential to cause severe damage to a host system if incorrectly triggered (Davis, A.E., 1988, Ann. Rev. Immunol., 6: 595-628; Frank, M.M., 1993, In: Complement in Health and Disease, 2nd Edition, Whaley, K. et al. eds., Kluwer Academic Publishers, Dordrecht, p. 229) and if its activity is diminished then it has the potential to leave the host open to attack from infecting pathogens.

This is particularly the case with patients suffering from Factor H (FH) deficiency which leads to an uncontrolled activation of the complement system resulting in a depletion of serum complement. Factor H deficient patients are susceptible to recurrent bacterial infection (particularly meningitis) and may not be able to clear immune complexes efficiently from circulation, resulting in glomerulonephritis.

Factor H is an important complement regulator which controls activation by its virtue to bind to native and complexed C3b and to serve as a cofactor in the Factor I mediated conversion of C3b to haemolytically inactive iC3b (Whaley, K. and Ruddy, S., 1976, J. Exp. Med., 144: 1147). It thereby acts as an antagonist to factor B and holds in check the alternative pathway activation, a positive feedback loop in which C3b

complexes with factor B, after which the serine protease factor D activates factor B by proteolysis, to form the alternative pathway C3 convertase, C3bBb. Factor H has a further important regulatory function as it can accelerate the decay of the C3 convertase by displacing Bb from the complex (Whaley, K. and Ruddy, S., 1976, Science, 193: 1011). Absence of factor H results in uncontrolled turnover of the alternative pathway. Because C3b is an integral component of the C5 convertases of both classical and alternative pathways, the binding of factor H to C3b also regulates C5 convertase activity (Whaley, K. and Ruddy, S., 1976, Science, 193: 1011). Thus factor H plays a key role in controlling the alternative pathway C3 convertase activity and also the activities of the C5 convertases of both classical and alternative pathways.

No complement regulatory activity has as yet been ascribed to the recently characterized variant factor H related serum glycoproteins of 39/43 kDa and 24/29 kDa (Timmann, C. et al., 1991, J. Immunol., 146:1265; Estaller, C. et al., 1991, J. Immunol., 146: 3190; Schwaeble, W. et al., 1991, Eur J. Biochem., 198: 399 - 404; Skerka, C. et al., 1991, J. Biol. Chem., 266: 12015; Zipfel, P.F. and Skerka, C., 1994, Immunology Today, 15: 121). These factor H related mRNAs are exclusively expressed in the liver (Schwaeble, W. et al., 1991, Immunobiol., 182:307) and encoded by at least two different factor H related genes (Estaller, C. et al., 1991, J. Immunol., 146: 3190; Hourcade, D. et al., 1991, Abstr. XIVth Int. Complement Workshop, Complement Inflamm., 8: 163; Zipfel, P.F. and Skerka, C., 1994, Immunology Today, 15: 121).

Factor H comprises a number of independently folded domains (CCP modules or short consensus repeats - SCRs) of approximately 60 amino acid (aa) residues with a framework of highly conserved residues involving 4 cysteine, 1 tryptophane and 2 proline residues. In human serum, two different FH glycoproteins of 155 kDa (FHp155) and of 43 kDa (FHp43) are known (Schwaeble. W. et al., 1987, Eur. J. Immunol., 17: 1485; Ripoche, J. et al., 2988, Biochem. J., 249: 593; Schwaeble, W. et al., 1991, Eur. J. Biochem., 198: 399-404; Estaller, C. et al., Eur. J. Immunol., 21:

799) and both forms express cofactor (i.e. complement regulatory) activity in the FI (Factor I) mediated conversion of C3b to iC3b (Misasi, R. *et al.*, 1989, Eur. J. Immunol., 19: 1765 - 1768). See also Whaley, K. and Ruddy, S., 1976, J. Exp. Med. 144: 1147-1163; Whaley, K. and Ruddy, S., 1976, Science, 193: 1011-1013.

According to the present invention there is provided a molecule comprising at least complement control protein (CCP) modules (Reid, K.B.M. *et al.*, 1986, Immunol. Today, 7: 230-234) 1-4 of complement factor H, or a molecule resulting from partial modification thereof or an allelic mutant thereof.

By "partial modification" and "partially modified" is meant, with reference to amino acid sequences a partially modified form of the molecule which retains substantially the properties of the molecule from which it is derived, although it may of course have additional functionality. Partial modification may, for example, be by way of addition, deletion or substitution of amino acid residues. Substitutions may be conserved substitutions. Hence the partially modified molecules may be homologues of the molecules from which they are derived. They may, for example, have at least 40% homology with the molecules from which they are derived. They may for example have at least 50, 60, 70, 80, 90 or 95% homology with the molecules from which they are derived. Similarly nucleotide sequences encoding the molecules or amino acid sequences may be partially modified to code for any such modifications to an amino acid sequence or molecule. Nucleotide sequences may also of course be modified such that they still code for the same amino acid residues but have a different nucleotide sequence.

The molecule may for example comprise CCP modules 1-4, 1-5 or 1-6 of complement factor H, or a molecule resulting from partial modification thereof or an allelic mutant thereof.

The present inventor have found that, surprisingly, truncated recombinant factor H expressed in yeast is approximately 10-100 fold more potent (see Figure 4) than the serum protein FHp155, and that this potency is to be found particularly in constructs representing CCP modules 1-6, CCP modules 1-5, and CCP modules 1-4. For example (Figure 4) at a 100 nM concentration a 30-40 fold increase in efficacy is observed. This specific potency in CCP modules (SCRs) 1-4, 1-5 and 1-6 has not previousl been suggested or disclosed.

The complement factor H may be human complement factor H or it may for example be a different animal complement factor H, for example rat complement factor H.

The molecule may comprise FHp43, or a molecule resulting from partial modification thereof or an allelic mutant thereof.

The molecule may be for use in inhibiting complement activation.

Hence a molecule according to the present invention may have increased complement inhibitory activity compared to that of FHp155, i.e. it may have an enhanced efficacy. A molecule according to the present invention comprises at least CCP modules 1-4 of FHp43. It may for example comprise at least CCP modules 1-4, 1-5 or 1-6 of FHp43.

A molecule comprising human factor H CCP modules 1-4, 1-5 or 1-6 may have the sequence of SEQ ID NO: 9, 10 or 11 respectively. A molecule comprising rat factor H and having CCP modules 1-7 may have the sequence of SEQ ID NO: 14.

The present inventors have found that the C-terminal 180 amino acids of FHp43 may be removed without significant loss of the complement inhibitory function

of FHp43. Hence molecules according to the present invention may have C-terminal deletions of for example about 180 amino acids, when compared to FHp43.

The regulatory activity of these molecules may be used for example in preventing tissue damage due to myocardial infarction, ischemia (for example limb and gut ischemia), infarction of neural tissue, in treating the adult respiratory distress syndrome, rheumatoid arthritis and thermal injuries. The molecules may be used as a fluid phase regulator of complement activity. They may for example be used to improve the biocompatability of artificial membranes by e.g. coating haemofiltration membranes with immobilised FH polypeptides in order to reduce complement activation or by encapsulating xenografts in artificial membranes coated with FH polypeptides. Fusion proteins may be made comprising a FH protein according to the present invention fused to a membrane anchor in order to act as a potent complement regulator on the surface of transfected (or transformed) cells and transgenic animals. Such membrane anchored molecules may be used to reduce xenograft rejection using xenotransplant organs. Spacer residues may be added between the membrane anchor and the FH protein in order to increase or optimise the efficacy of the FH protein (Adams, E.M. *et al.*, 1991, J. Immunol., 147: 3005). Methods of transformation and transfection of cells are well known in the art and where reference is made to transfection, reference is also to transformation and *vice versa*.

Molecules according to the present invention may be modified such that they have an increased half-life in order that they may have a prolonged protective effect upon a patient. Particular molecules may for example comprise dimeric or trimeric forms of molecules according to the present invention. For example a molecule may comprise a trimer of CCP modules 1-4 or a trimer of FHp43.

Also provided according to the present invention is the use of a molecule according to the present invention in the manufacture of a medicament for inhibiting

complement activation. Also provided according to the present invention is a method of manufacture of a medicament for inhibiting complement activation, comprising the use of a molecule according to the present invention.

Also provided according to the present invention is a method of inhibiting complement activation comprising the use of a molecule according to the present invention.

Although human Factor H has previously been clones, researchers have so far failed to clone rat Factor H. The present inventors have now succeeded in isolating and sequencing rat FH 4.3 and FH1.0 mRNA and so according to the present invention there is also provided a nucleotide sequence having the sequence of SEQ ID NO: 1 (Figure 1 - FH4.3) encoding rat FH 4.3 kb mRNA, together with a nucleotide sequence having the sequence of SEQ ID NO: 2 (Figure 1 - FH1.0) encoding rat FH 1.0 kb mRNA. The present invention also extends to partially modified forms of the nucleotide sequences and to polypeptides derived from them and partially modified forms thereof.

FHp155 and FHp43 may be readily isolated and purified (Misasi, R. *et al.*, Eur. J. Immunol., 1989, 19: 1765-1768; Sim, R.B. *et al.*, 1993, Int. Rev. Immunol., 10: 65; Sim, R.B. *et al.*, 1993, Meth. Enzymol., 223: 13 and references therein) and the genes encoding the proteins may be isolated using standard techniques. Standard expression systems, for example MaxBac (Invitrogen) may be used to synthesise the isolated protein (see Sharma, A.K. and Pangburn, M.K., 1994, Gene, 143: 301).

The ability of the molecules of the present invention to inhibit complement activation may be readily shown by activating complement with antigen-antibody complexes (classical pathway) or zymosan (alternative pathway) in the presence of the molecules of the present invention and assaying levels of C3a, C5a and C5b-9

complement components using commercially available reagents (Amersham) and ELISA (enzyme linked immunosorbent assay).

The alternative pathway C3 and C5 convertases ((C3b)$_n$BbP) and classical pathway C5 convertase (C4b2a3b) may be readily prepared from for example rat or human components and the activity of the factor H molecules of the present invention on the formation and stability of each convertase and on C5 activation may be assayed using haemolytic assay systems (Sim *et al.*, 1993, *supra*).

The ability of the molecules of the present invention to inhibit complement activation and limit tissue injury *in vivo* may be determined using for example a model of perfusion injury of ischaemic myocardium (Weisman, H.F *et al.*, 1990, Science, 249: 146) and a model of antibody-dependent experimental allergic encephalomyelitis (Piddlesden, S. *et al.*, 1990, Clin. Exp. Immunol., 83: 245).

The molecules of the present invention may be readily coupled to artificial membranes, for example dialysis membranes, as follows. Using cuprophan-cellulose membranes (Enka-Azko, Wuppertal, Germany), the following steps may be performed:

i) Activation of the membrane:

1,1'-Carbodiimidazole (Kennedy, J.F. and Paterson, M., 1993, Polymer. Intern., 32: 71;

Chlorformic acid-p-nitrophenylester (Vandorne, F. *et al.*, 1991, Makromol. Chem., 192: 773);

Cyanogen bromide (Kennedy, J.F. and Patterson, M., 1993, *supra*)

ii) Coupling of spacers:

Use of aliphatic diamines (e.g. 1,12 Diaminododecane, Kery *et al.*, 1991, Carbohydr. Res., 209: 83);

Use of 6-aminocaproicacid (Burton, S.C., 1991, J. Chromatogr., 587: 271);

Use of aminosubstituted aliphatic thiols (Kery *et al.*, 1991, *supra*)

iii) Coupling of the peptide:

Activation of the N-terminal spacer by thiophosgen;

Activation of a carboxyterminal spacer using alternatively the acid method or the addition of coupling reagents (e.g. DCC or EDC, Royer, G.P. and Anantharmaiah, G.M., 1979, J. Am. Chem. Soc., 101: 3395; Bodanszky, M. and Bodanszky, A., 1984, K. Hafner *et al.*, Hrsg, Bd. 21, Springer-Verlach, Berlin);

Activation of S-terminal spacer by 2,2'-Dithiodipyridine and coupling via cysteine residues.

The effect of uncoated and coated membranes (above) upon complement activation may be readily quantified using C3a, C5a and C5b-9 assays (Chenoweth, D.E., 1987, Contr. Nephrol., 59: 51 and as described above).

According to a further aspect of the invention, there is provided a DNA molecule, which may be in recombinant or isolated form, comprising a sequence encoding a molecule according to the present invention.

The coding sequence may be operatively linked to an expression control sequence sufficient to drive expression. Recombinant DNA in accordance with the invention may be in the form of a vector. The vector may for example be a plasmid, cosmid or phage. A vector may include at least one selectable marker to enable selection of cells transfected (or transformed) with the vector. Such a marker or markers may enable selection of cells harbouring vectors incorporating heterologous DNA. The vector may contain appropriate start and stop signals. The vector may be an expression vector having regulatory sequences to drive expression. Vectors not having regulatory sequences may be used as cloning vectors (as may expression vectors).

Cloning vectors can be introduced into suitable hosts (for example *E. coli*) which facilitate their manipulation.

According to another aspect of the invention, there is therefore provided a host cell transfected or transformed with DNA according to the present invention. Such host cells may be prokaryotic or eukaryotic. Eukaryotic hosts may include yeasts, insect and mammalian cell lines. Expression hosts may be stably transformed. Unstable and cell-free expression systems may of course also be used.

DNA of the invention may also be in the form of a transgene construct designed for expression in a transgenic plant or animal. In principle, the invention is applicable to all animals, including birds such as placental mammals, (for example cattle, sheep, goats, water buffalo, camels and pigs), domestic fowl, amphibian species and fish species. The protein may be harvested from body fluids or other body products (such as eggs or milk, where appropriate). Such mammalian transgenic mammary expression systems are well known - see for example WO 88/00239, WO 90/05188 and WO 94/16570. The β-lactoglobulin promoter may be used in transgenic mammary expression systems.

Expression hosts, particularly transgenic animals, may contain other exogenous DNA to facilitate the expression, assembly, secretion and other aspects of the biosynthesis of molecules of the invention.

The invention is in principle capable of accommodating the use of synthetic DNA sequences, cDNAs, full genomic sequences and "minigenes", i.e. partial genomic sequences containing some, but not all, of the introns present in the full length gene.

DNA in accordance with the invention can in principle be prepared by any convenient method involving coupling together successive nucleotides, and/or ligating

oligo- and/or poly-nucleotides, including *in vitro* processes, as well as by the more usual recombinant DNA technology.

The invention will be further apparent from the following description, with reference to the several figures of the accompanying drawings, which show, by way of example only, forms of complement inhibition. Of the figures:

Figure 1   shows sequence alignments of the nucleotide sequences of four different types of rat factor H mRNA transcripts (rFH4.3, rFH2.7, rFH1.8 and rFH1.0; SEQ ID NOs: 1, 3, 4 and 2 respectively). Start and stop-codons are underlined, the polyadenylation initiation signal is written in italics;

Figure 2   shows a cofactor assay showing the functional activity of recombinant human FHp43. Lanes are as follows: Lane 1 - C3b with human Factor I (FI); lane 2 - C3b with rat FI; lane 3 - C3b with human FI and recombinant rat FHSCR1-7; lane 4 - C3b with human FI and recombinant human FHp43 (10 mM); and lane 5 - C3b with rat FI and purified human factor H; and

Figure 3   shows a cofactor assay showing the functional activity of recombinant rat FHSCR1-7. Lanes are as follows: Lane 1 - C3b with human FI; lane 2 - C3b with rat FI; lane 3 - C3b with human FI and recombinant human factor H; lane 4 - C3b with human FI and recombinant rat factor H; lane 5 - C3b with rat FI and recombinant rat FHSCR1-7; lane 6 - C3b with rat factor I and 10 mM recombinant rat FHSCR1-7; and lane 7 - C3b with human factor I and 10 mM recombinant FHp43.

Figure 4   shows the results of a cofactor assay performed to compare the functional activity of truncated recombinant human factor H SCR1-4, SCR1-5 and SCR1-6 with that of purified serum FHp155. The values given are arbitrary values representing the relative abundance of the 43 kDa C3b cleavage product obtained by the

factor I-mediated cleavage of ^{125}I-labelled C3b using densitometry. COncentration of purified recombinant and native factor H proteins added to the assay are given in the left column.

- 12 -

EXPERIMENTAL

With the following experiments, a truncated recombinant human and rat factor H are expressed in a high efficiency yeast expression system. The yield of expression is estimated to be in a range of up to 5mg of recombinant protein per litre of yeast culture.

Figures 2 and 3 show the results of the cofactor assays described below. The presence of an α' band at 43 kDa (a cleavage product of the α-chain of C3b) indicates cofactor activity (Figure 2, lane 4; Figure 3, lanes 3, 5, 6 and 7). Hence both the recombinant human FHp43 and rat FHSCR1-7 peptides cooperate with factor I in a species specific manner and, surprisingly, exhibit cofactor activity even at low concentrations (10 mM) when incubated with C3b and factor I of the corresponding species.

Materials and Methods

Isolation and characterization of 4 different factor H or factor H related gene products of the rat

Using a rat liver cDNA library in λ-ZAP II (#937506 STATAGENE, La Jolla, CA), cDNA clones rFH4.3, rFH1.8, rFH2.7 and rFH1.0 were isolated as follows. Approximately 300,000 colonies were screened with a 5' specific PstI/XhoI cDNA subfragment of the mouse factor H cDNA clone MH8 (Kirstensen, T. *et al.*, 1986, J. Immunol., <u>136</u>: 3407). From eighteen hybridizing plaques obtained in the rescreen procedure, the four clones listed above were analysed further. The pBluescript SK- plasmid containing the cDNA insertions of interest were rescued from the λ-ZAP II phagemid by *in vivo* excision. The cDNA sequences of the 4 different types of clones was determined by sequencing both strands using the Sanger dideoxy chain termination method with Sequenase II (RTM) and the reagent kit (USB, Cleveland, USA).

- 13 -

RNA extraction and Northern blot analysis

Total RNA was isolated according to standard methods (Chirgwin, J.W. *et al.*, 1979, Biochemistry, 18: 5294), quantified by measuring the absorbence at 260 nm, separated on a formaldehyde-containing 1.2% agarose gel and blotted to Hybond N filters. Agarose gel electrophoresis, RNA transfer and hybridization of blots were performed by standard techniques (Sambrook, J., Frisch, E.F., and Maniatis, T.: Molecular cloning. A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, New York, 1989). Northern blot filters were probed with a 5'-specific 553 bp long PstI/XhoI restriction subfragment of the murine factor H clone MH8 encoding SCR 1-2 of mouse factor H, and the 867 bp long cDNA insert of the rat specific factor H clone rFH1.0. The probes were used at a concentration of 5×10^6 cpm of ^{32}P labelled cDNA/ml hybridization solution. Hybridization was performed at 65 °C in the absence of formamide. The washing of the Northern blots was carried out according to standard procedures (Sambrook et al., 1989, *supra*). The last washing step was performed in 0.3x SSC for 1 hour at 65 °C.

In order to obtain recombinant proteins of lower molecular weight than the naturally occuring factor H serum proteins and in order to opimise complement regulatory activity, we have modified the coding sequence of the human 1.8 kb factor H mRNA sequence. The modifications include a linker sequence insertion to enable an in frame cloning of the first codon for position 1 of the mature factor H protein with the coding sequence of the α-secretory factor contained in the yeast expression vector as well as the insertion of translation termination codons in order to obtain truncated forms of recombinant human factor H. Three constructs of different length were produced, encoding the SCR-motifs 1-4, SCR1-5, and SCR1-6. The pairs of oligonucleotide primers used to amplify the different stretches of coding sequence for human factor H (Schwaeble, W. *et al.*, 1987, Eur. J. Immunol., 17: 1485; Ripoche, J. *et al.*, 1988 Biochem. J., 249: 593; Schwaeble, W. *et al.*, 1991, Eur. J. Biochem., 198: 399-404; Estaller, C. *et al.*, Eur. J. Immunol., 21: 799) by PCR are listed below.

For the construct encoding SCR 1-4:

Forward primer (sense orientation)

3' gta **gaa ttc** GAA GAT TGCAAT GAA CTT 5' (SEQ ID NO: 5)

Reverse primer (ligates and introduces a stop codon at the end of the coding sequence for SCR4, anti-sense orientation)

3' AGA GGA TAT AGA GTC TTC TAA ACT **cgc cgg cgg** 5' (SEQ ID NO: 6)

For the construct encoding SCR 1-5:

Forward primer (sense orientation)

3' gta **gaa ttc** GAA GAT TGCAAT GAA CTT 5' (SEQ ID NO: 5)

Reverse primer (ligates and introduces a stop codon at the end of the coding sequence for SCR5, anti-sense orientation)

3' ATG AGT GGA AAT TCC TAA TTT ACT **cgc cgg cgg** 5' (SEQ ID NO: 7)

For the construct encoding SCR 1-6:

Forward primer (sense orientation)

3' gta **gaa ttc** GAA GAT TGCAAT GAA CTT 5' (SEQ ID NO: 5)

Reverse primer (ligates and introduces a stop codon at the end of the coding sequence for SCR6, anti-sense orientation)

3' GCA TCT GGT ATG AAA GGT CAT ACT **cgc cgg cgg** 5' (SEQ ID NO: 8)

Each of the three different PCR products was digested with the restriction endonucleases EcoRI and NotI and subcloned in the polylinker region of the EcoRI/ NotI digested yeast expression vector pPICZαA (Invitrogen BV, Leek, The Netherlands). Plasmids were grown in the E.coli strain TOP10F and sequenced to confirm the in frame cloning and the absence of cloning artifacts within the coding sequence. These constructs were used to transfect Pichia Pastoris host cells (strain SMD 1168) , transformants selected on YPD/Zeocin agar and genomic transmission of the constructs tested by PCR. Expression of the constructs was performed according to the manufacturer's protocol

The three different constructs therefore encode recombinant proteins representing different parts of the N-terminal sequence of human factor H

The protein sequence of the truncated recombinant human factor H protein SCR1-4 (a protein of 207 aa and 23 kDa) is SEQ ID NO: 9.

The protein sequence of the truncated recombinant human factor H protein SCR1-5 (a protein of 265 aa and 30 kDa) is SEQ ID NO: 10.

The protein sequence of the truncated recombinant human factor H protein SCR1-6 (a protein of 329 aa and 37 kDa) is SEQ ID NO: 11

In order to provide reagents that can be used to assess the therapeutic potential of recombinant factor H in rat experimental animal models, a truncated recombinant protein for rat factor H was prepared taking advantage of our rat factor H cDNA for FH4.3 (shown in figure 1 below):

As the functionally relevant SCR domains of rat factor H have not yet been mapped precisely, we expressed a slightly larger protein representing the 7 N-terminal SCR domains.

The following oligonucleotides were used to construct the
cDNA encoding rat factor H SCR 1-7:
Forward primer (sense orientation)
3' gta **gaa ttc** GAA GAT TGT AAA GGT CCT CCT CC 5' (SEQ ID NO: 12)
Reverse primer (ligates and introduces a stop codon at the end of the coding sequence for SCR7, anti-sense orientation)
3' TTT ACG CAG GCA TAG TTC ATT **aga** tct cc 5' (SEQ ID NO: 13)

- 16 -

The PCR product was digested with the restriction endonucleases EcoRI and XbaI and subcloned in the polylinker region of the EcoRI/XbaI digested yeast expression vector pGAPZαA (Invitrogen BV, Leek, The Netherlands). Plasmids were grown in the E.coli strain TOP10F and sequenced to confirm the in frame cloning and the absence of cloning artifacts within the coding sequence. These constructs were used to transfect Pichia Pastoris host cells (strain SMD 1168) , transformants selected on YPD/Zeocin agar and genomic transmission of the constructs tested by PCR. Expression of the constructs was performed according to the manufacturer's protocol. After electroporation, Pichia pastoris cells were plated on MD plates (containing dextrose) and grown at 30 %C for 48 hours. Single colonies were picked from these plates and replated on Methanol containing MM plates (without dextrose) to select for AOX1- disrupted transformants which have the cDNA of interest inserted into the polylinker region. Alcohol oxidase genes AOX1 and AOX2 allow the metabolism of methanol, thereby providing a source of carbohydrates. MM plates (without dextrose) provide no other source of carbohydrates and so AOX1-disrupted transformants, which have a reduced ability to metabolise methanol, were recognised by their slower growth on dextrosol-free MM plates. The insertion of the cDNA construct of interest was further confirmed by PCR analysis of genomic DNA isolated from poorly growing colonies. In order to select for such colonies that secrete high rates of recombinant factor H, twenty AOX1-disrupted colonies were inoculated each in 10 ml of BMGY medium (Invitrogen) in a 50 ml tube and cultured at 30 °C with vigorous shaking (>200 rpm) for 48 hours to saturation (OD$_{600}$ = 10.0-20.0). Cells were harvested by centrifugation for 10 minutes at room temperature at 4000 g, supernatant discarded and the pellet resuspended in 2 ml of BMMY (Invitrogen) medium. This time, tubes were only covered with two layers of sterile gauze and again, incubation occurred at 30°C with vigorous shaking (>200 rpm) for 48 hours. Cells were pelleted as before and supernatants analysed by Western blot analysis.

The protein sequence of the truncated recombinant rat factor H protein SCR1-7 (a protein of 428 aa and 49 kDa) is SEQ ID NO: 14

After induction of expression, supernatants from all of the 4 different constructs were run through an ion exchange column an the recombinant factor H proteins purified of Cl-4B sepharose coupled to polyclonal anti human or polyclonal anti-rat antibodies.

The recombinant truncated rat and human factor H proteins were assessed for complement regulatory activity and compared with purified serum factor H using a factor H dependent cofactor assay.

Cofactor assay

Functional activity of recombinant rat and human factor H was determined in a factor H dependent factor I mediated C3b cleavage assay. Therefore, human C3b and factor I were purified from peripheral blood as previously described (Misasi, R. et al., 1989, Eur. J. Immunol., 19: 1765). In order to establish a species-specific variant of this assay, rat factor I was purified from 2 ml of rat serum by fluid phase liquid chromatography using Pharmacia FPLC apparatus P500 and a Pharmacia Mono S HR 5/5 column eqilibrated with PE buffer at pH 6. Separation of serum proteins occurred by addition of PE-buffer plus 1M NaCl at pH 6 and a flow rate of 1 ml/min. Fractions were depleted of factor H by immune-chromatography using a Sepharose C14b column preabsorbed with the human anti-factor H monoclonal antibody OX23 (Schwaeble, W. et al., 1987, Eur. J. Immunol., 17: 1485). Human C3 and factor I were prepared from human serum as described earlier (Hammer, C.H.; Wirtz, G.H.; Renfer, L.; Gresham, H.D.; and Tack, B.F. J. Biol. Chem. 1981, 256: 3995 ; Lambris, J.D. ; Dobson, N.J.; and Ross, G.D. J.Exp.Med. 1980. 152: 1625. C3b was prepared by limited tryptic digestion of C3 (Bokisch V.A.; Müller-Eberhard, H.J.; and Cochrane, C.G. J.Exp.Med. 1969. 129: 1109) and consecutive chromatography on Sephadex G-100 (equilibrated in 10 mM sodium phosphate / 150 mM NaCl buffer, pH7.3) This preparation was radiolabelled with [125]I (1mCi037MBq of Na ^{125}I per 200 µg C3b) by the Iodogen method (Iodobeads purchased from Pierce Chemical Co. Rockford, IL) The specific activity was about 10^6 cpm /µg C3b. In the assay procedure 300 000 cpm of ^{125}I-labelled C3b was mixed with

increasing concentrations of recombinant human factor H proteins FH1-4, FH 1-5 and FH1-6 and serum factor H and 0.2 µg of purified human factor I in PBS containing 2 mM DFP in a total volume of 100µl and incubated for 30 minutes at 37°C. Cleavage of C3b was monitored by SDS-PAGE and autoradiography by the generation of the 73 kDa and 43 kDa cleavage products of the α-chain of C3b. Production of the 43 kDa cleavage product was indicative of cofactor activity.

Samples were analysed by SDS-PAGE under reducing conditions on a 9.5% SDS gel. Gels were dried and finally exposed to autoradiography on X-ray films.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

    (i) APPLICANT:
        (A) NAME: The University of Leicester
        (B) STREET: University Road
        (C) CITY: Leicester
        (E) COUNTRY: United Kingdom
        (F) POSTAL CODE (ZIP): LE1 7RH

    (ii) TITLE OF INVENTION: Complement Inhibitor

    (iii) NUMBER OF SEQUENCES: 14

    (iv) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 4229 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: double
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```
TCGAGTCAAC TGCTCCCAGA TAGATCCAAG ACATGAGACT GTCAGCAAGA ATTATTTGGC        60

TTATATTATG GACTGTTTGT GTAGCAGAAG ATTGTAAAGG TCCTCCTCCA AGAGAAAATT       120

CAGAAATTCT CTCAGGTTCG TGGTCTGAAC AACTATATTC AGAAGGCACT CAGGCAACCT       180

ACAAATGCCG CCCTGGATAC CGAACACTTG GTACTATTGT AAAAGTATGC AAGAATGGAG       240

AATGGGTACC TTCTAACCCA TCAAGGATAT GTCGGAAAAG GCCATGTGGG CATCCCGGAG       300

ACACACCCTT TGGGTCCTTT AGGCTGGCAG TTGGATCTGA ATTTGAATTT GGTGCAAAGG       360

TTGTTTATAC ATGTGATGAA GGGTACCAAC TATTAGGTGA AATTGATTAC CGTGAATGTG       420

ATGCAGATGG GTGGACCAAT GATATTCCAA TATGTGAAGT TGTGAAGTGC TTGCCAGTGA       480

CAGAACTGGA GAATGGAAGA ATTGTGAGTG GTGCAGCCGA ACCAGACCAG GAATATTATT       540

TTGGACAGGT GGTACGCTTT GAATGCAACT CCGGCTTCAA GATTGAAGGA CAGAAAGAAA       600

TGCACTGCTC ATAAAATGGC CTCTGGAGCA ATGAAAAGCC ACAGTGTGTG GAAATTTCTT       660
```

```
GCCTGCCACC ACGAGTTGAA AATGGAGATG GTATATATCT GAAACCAGTT TACAAGGAGA      720

ATGAAAGATT CCAATATAAA TGTAAGCAAG GTTTTGTGTA CAAAGAAAGA GGGGATGCTG      780

TCTGCACGGG TTCTGGATGG AATCCTCAGC CTTCCTGTGA AGAAATGACA TGTTTGACTC      840

CATATATTCC AAATGGTATC TACACACCTC ACAGGATTAA ACACAGAATT GATGATGAAA      900

TCAGATATGA ATGTAAAAAT GGCTTCTATC CTGCAACCCG ATCACCTGTT TCAAAGTGTA      960

CAATTACTGG CTGGATCCCT GCTCCAAGAT GTAGCTTGAA ACCTTGTGAT TTTCCACAAT     1020

TCAAACATGG ACGTCTGTAT TATGAAGAAA GCCGGAGACC CTACTTCCCA GTACCTATAG     1080

GAAAGGAGTA CAGCTATAAC TGTGACAACG GGTTTACAAC GCCTTCACAG TCATACTGGG     1140

ACTACCTTCG TTGCACAGTA AATGGGTGGG AGCCTGAAGT TCCATGCCTC AGGCAATGTA     1200

TTTTCCATTA TGTGGAATAT GGAGAATCTT CATACTGGCA AGAAGATAT ATAGAGGGTC      1260

AGTCTGCAAA AGTCCAGTGT CACAGTGGCT ATAGTCTTCC AAATGGTCAA GATACATATT     1320

ATTGTACAGA GAATGGCTGG TCCCCTCCTC CCAAATGCGT CCGTATCAAG ACTTGTTCAG     1380

TATCAGATAT AGAAATTGAA AATGGGTTTT TTCTGAATC TGATTATACA TATGCTCTAA      1440

ATAGAAAAAC ACGGTATAGA TGTAAACAGG GATATGTAAC AAATACCGGA GAAATATCAG     1500

GAATAATTAC TTGTCTTCAA GATGGATGGT CACCTCGACC CTCATGCATT AAGTCTTGTG     1560

ATATGCCTGT ATTTGAGAAT TCTATGACTA AGAATAATAA CACATGGTTT AAACTCAATG     1620

ACAAATTAGA CTATGAATGT CACATTGGAT ATGAAAATGA ATATAAACAT ACCAAAGGCT     1680

CTATAACATG TACTTATGAT GGATGGTCTA GTACACCCTC CTGTTATGAA AGAGAATGCA     1740

GCATTCCCCT GTTACACCAA GACTTAGTTG TTTTTCCCAG AGAAGTAAAA TACAAAGTTG     1800

GAGATTCGTT GAGTTTCTCT TGCCGTTCAG GACACAGAGT TGGAGCAGAT TTAGTGCAAT     1860

GCTACCACTT TGGATGGTCC CCTAATTTCC AACGTGTGA AGGCCAAGTA AAATCATGTG      1920

ACCAACCTCT TGAAATCCCG AATGGGGAAA TAAAGGGAAC AAAAAAAGTT GAATACAGCC     1980

ATGGTGACGT GGTGGAATAT GATTGCAAAC CTAGATTTCT ACTGAAGGGA CCCAATAAAA     2040

TCCAGTGTGT TGACGGGAAG TGGACAAGGT TGCCGATATG CGTTGAGTAT GAGAGAACAT     2100

GTGGAGACCT TCCTGAACTT GAGCATGGCT CTGTCAAGTT ATCTGTCCCT CCCTACCATC     2160

ATGGAGATTC AGTGGAGTTC ACTTGTACAG AAACCTTCAC AATGATTGGA CATGCAGTAG     2220

TTTTCTGCAT TAGTGGAAGG TGGACCGAGC TTCCTCAATG TGTTGCAACA GATCAACTGG     2280

AGAAGTGTAA AGCCCCGAAG TCAACTGGCA TAGATGCAAT TCATCCAAAT AAGAATGAAT     2340
```

- 21 -

```
TTAATCATAA CTTTAGTGTG AGTTACAGAT GTAGACAAAA GCAGGAGTAT GAACATTCAA    2400

TCTGCATCAA TGGAAGATGG GATCCTGAAC CAAACTGTAC AAGCAAAAGA TTCTGCCCTC    2460

CTCCCCCGCA GATTCCAAAT GCCCAAGTGA TTGAAACCAC CGTGAAATAC TTGGATGGAG    2520

AAAAAGTATC TGTTCTTTGC CAAGATGGTT ACCTAACTCA GGGCCCAGAA GAAATGGTGT    2580

GTAAACATGG AAGGTGGCAG TCGTTACCAC GCTGCACGGA AAAAATTCCA TGTTCCCAGC    2640

CCCCTAAAAT TGAACATGGA TCTATTAAGT CGCCCAGGTC CTCAGAAGAG AGGAGAGATT    2700

TAATTGAGTC CAGCAGTTAT GAACACGGAA CTACATTCAG CTATTGCTGT AGAGATGGAT    2760

TCAAGATATC TGAAGAAAAT AGGGTAACCT GCAACATGGG AAAATGGAGC TCTCTGCCTC    2820

GTTGTGTTGG AATACCTTGT GGACCCCCAC CTTCAATTCC TCTTGGTATT GTTTCTCATG    2880

AACTAGAAAG TTACCAATAT GGAGAGGAGG TTACATACAA TTGTTCTGAA GGCTTTGGAA    2940

TTGATGGACC AGCATTTATT AAATGTGTAG GAGGACAGTG GTCTGAACCT CCCAAATGCA    3000

TAAAAACTGA TTGTGACAAC TTGCCCACAT TTGAAATTGC CAAACCGACA GAAAAGAAAA    3060

AAAAATCATA CAGGTCAGGA GAACAAGTGA CATTCAGATG TCCACCTCCG TATCGAATGG    3120

ATGGCTCTGA CATTGTCACA TGTGTTAATA CGAAGTGGAT TGGACAGCCG GTATGCAAAG    3180

ATAATTCCTG TGTGAATCCA CCACATGTGC CAAATGCTAC TATACTAACA AGGCACAAGA    3240

CTAAATATCC ATCTGGTGAC AAAGTACGTT ATGACTGTAA TAAACCTTTT GAATTATTTG    3300

GGGAAGTGGA AGTGATGTGC CAAAACGGGA TTTGGACAGA ACCACCGAAA TGCAAAGATT    3360

CAACAGGGAA ATGTGGGCCT CCTCCACCTA TTGACAATGG AGACATCACC TCCTTGTCAT    3420

TACCAGTATA TGCACCATTA TCATCAGTTG AATATCAATG CCAGAACTAT TATCTACTTA    3480

AGGGAAATAA GATAGTAACA TGTAGAAATG GAAAGTGGTC TCAGCCACCA ACCTGCTTAC    3540

ATGCATGTGT GATACCAGAA GATATTATGG AAAAACATAA TATAGTTCTC AGATGGAGGG    3600

AAAATGCAAA GATTTATTCC CAATCAGGGG AGAATATTGA ATTCATGTGT AAACCTGGAT    3660

ATAGAAAATT CAGAGGATCA CCTCCGTTTC GTACAAAGTG CATTGAGGGT CACATCAATT    3720

ATCCCACTTG TGTATAAAAT CGCTATACAA TTATTAGTAA ACCTTATGGA TGAGAAATGC    3780

ACATGTATAT TACTAATACA GTTTGAATTT ACATTTAAAT ATTGTTTAGC TCATTTCCTC    3840

TAATAAGTAT ATAAACTTTT TTTATATGGT GGTTAATCAG TAACTTTACA GACTGTTGCC    3900

ACAAAGCAAG AACATTACAT TCAAAACTCC TAATCCAAAT ATGATATGTC CAAGGACAAA    3960

CTATGTCTAA GCAAGAAAAT AAATGTTAGT TCTTCAATGT CTGTTTTTAT TCAGGACCTT    4020
```

TCAGATTTTC TTGGATACCT TTTGTTAGGT TCTGATTCAC AGTGAGTGGA AGACACACTG   4080

ACTCTGACTT CAAATTAGTA TTACTTGCAA TACATTAACA ACCAAACTAT CATAATATCA   4140

CAAATGTATA CAGCTAATTA CTGTGTCCTA CCTTTGTATC AATAAAGAAA TCTAAGAAAG   4200

TTCTTGCTTA AAAAAAAAAA AAAAAAAAA   4229

(2) INFORMATION FOR SEQ ID NO: 2:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 866 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: double
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TCGAGTCAAC TGCTCCCAGA TAGATCCAAG ACATGAGACT GTCAGCAAGA ATTATTTGGC   60

TTATATTATG GACTGTTTGT GTAGCAGAAG ATTGTAAAGG TCCTCCTCCA AGAGAAAATT   120

CAGAAATTCT CTCAGGTTCG TGGTCTGAAC AACTATATTC AGAAGGCACT CAGGCAACCT   180

ACAAATGCCG CCCTGGATAC CGAACACTTG GTACTATTGT AAAAGTATGC AAGAATGGAG   240

AATGGGTACC TTCTAACCCA TCAAGGATAT GTCGGAAAAG GCCATGTGGG CATCCCGGAG   300

ACACACCCTT TGGGTCCTTT AGGCTGGCAG TTGGATCTGA ATTTGAATTT GGTGCAAAGG   360

TTGTTTATAC ATGTGATGAA GGGTACCAAC TATTAGGTGA AATTGATTAC CGTGAATGTG   420

ATGCAGATGG GTGGACCAAT GATATTCCAA TATGTGAAGT TGTGAAGTGC TTGCCAGTGA   480

CAGAACTGGA GAATGGAAGA ATTGTGAGTG GTGCAGCCGA ACCAGACCAG GAATATTATT   540

TTGGACAGGT GGTACGCTTT GAATGCAACT CCGGCTTCAA GATTGAAGGA CAGAAAGAAA   600

TGCACTGCTC ATAAAATGGC CTCTGGAGCA ATGAAAAGCC ACAGTGTGTG GAAATTTCTT   660

GCCTGCCACC ACGAGTTGAA AATGGAGATG GATATAGAAA ATTCAGAGGA TCACCTCCGT   720

TTCGTACAAA GTGCATTGAG GGTCACATCA ATTATCCCAC TTGTGTATAA AATCGCTATA   780

CAATTATTAG TAAACCTTAT GGATGACACT TTGTTTAGAA ATGCACATGT ATATTACTAA   840

TACAGTTTGA ATTTACATTT GAAAAA   866

(2) INFORMATION FOR SEQ ID NO: 3:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 2715 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: double
        (D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```
TCGAGTCAAC TGCTCCCAGA TAGATCCAAG ACATGAGACT GTCAGCAAGA ATTATTTGGC          60

TTATATTATG GACTGTTTGT GTAGCAGAAG ATTGTAAAGG TCCTCCTCCA AGAGAAAATT         120

CAGAAATTCT CTCAGGTTCG TGGTCTGAAC AACTATATTC AGAAGGCACT CAGGCAACCT         180

ACAAATGCCG CCCTGGATAC CGAACACTTG GTACTATTGT AAAAGTATGC AAGAATGGAG         240

AATGGGTACC TTCTAACCCA TCAAGGATAT GTCGGAAAAG GCCATGTGGG CATCCCGGAG         300

ACACACCCTT TGGGTCCTTT AGGCTGGCAG TTGGATCTGA ATTTGAATTT GGTGCAAAGG         360

TTGTTTATAC ATGTGATGAA GGGTACCAAC TATTAGGTGA AATTGATTAC CGTGAATGTG         420

ATGCAGATGG GTGGACCAAT GATATTCCAA TATGTGAAGT TGTGAAGTGC TTGCCAGTGA         480

CAGAACTGGA GAATGGAAGA ATTGTGAGTG GTGCAGCCGA ACCAGACCAG GAATATTATT         540

TTGGACAGGT GGTACGCTTT GAATGCAACT CCGGCTTCAA GATTGAAGGA CAGAAAGAAA         600

TGCACTGCTC ATAAAATGGC CTCTGGAGCA ATGAAAAGCC ACAGTGTGTG TTGAAACCTT         660

GTGATTTTCC ACAATTCAAA CATGGACGTC TGTATTATGA AGAAAGCCGG AGACCCTACT         720

TCCCAGTACC TATAGGAAAG GAGTACAGCT ATAACTGTGA CAACGGGTTT ACAACGCCTT         780

CACAGTCATA CTGGGACTAC CTTCGTTGCA CAGTAAATGG GTGGGAGCCT GAAGTTCCAT         840

GCCTCAGGCA ATGTATTTTC CATTATGTGG AATATGGAGA ATCTTCATAC TGGCAAAGAA         900

GATATATAGA GGGTCAGTCT GCAAAAGTCC AGTGTCACAG TGGCTATAGT CTTCCAAATG         960

GTCAAGATAC ATATTATTGT ACAGAGAATG GCTGGTCCCC TCCTCCCAAA TGCGTCCGTA        1020

TCAAGACTTG TTCAGTATCA GATATAGAAA TTGAAAATGG GTTTTTTTCT GAATCTGATT        1080

ATACATATGC TCTAAATAGA AAAACACGGT ATAGATGTAA ACAGGGATAT GTAACAAATA        1140

CCGGAGAAAT ATCAGGAATA ATTACTTGTC TTCAAGATGG ATGGTCACCT CGACCCTCAT        1200

GCATTAAGTC TTGTGATATG CCTGTATTTG AGAATTCTAT GACTAAGAAT AATAACACAT        1260

GGTTTAAACT CAATGACAAA TTAGACTATG AATGTCACAT GGATATGAA AATGAATATA        1320

AACATACCAA AGGCTCTATA ACATGTACTT ATGATGGATG GTCTAGTACA CCCTCCTGTT        1380

ATGAAAGAGA ATGCAGCATT CCCCTGTTAC ACCAAGACTT AGTTGTTTTT CCCAGAGAAG        1440

TAAAATACAA AGTTGGAGAT TCGTTGAGTT CTCTTGCCG TTCAGGACAC AGAGTTGGAG        1500

CAGATTTAGT GCAATGCTAC CACTTTGGAT GGTCCCCTAA TTTCCCAACG TGTGAAGGCC        1560

AAGTAAAATC ATGTGACCAA CCTCTTGAAA TCCCGAATGG GGAAATAAAG GGAACAAAAA        1620
```

```
AAGTTGAATA CAGCCATGGT GACGTGGTGG AATATGATTG CAAACCTAGA TTTCTACTGA    1680

AGGGACCCAA TAAAATCCAG TGTGTTGACG GGAAGTGGAC AAGGTTGCCG ATATGCGTTG    1740

AGTATGAGAG AACATGTGGA GACCTTCCTG AACTTGAGCA TGGCTCTGTC AAGTTATCTG    1800

TCCCTCCCTA CCATCATGGA GATTCAGTGG AGTTCACTTG TACAGAAACC TTCACAATGA    1860

TTGGACATGC AGTAGTTTTC TGCATTAGTG GAAGGTGGAC CGAGCTTCCT CAATGTGTTG    1920

CAACAGATCA ACTGGAGAAG TGTAAAGCCC CGAAGTCAAC TGGCATAGAT GCAATTCATC    1980

CAAATAAGAA TGAATTTAAT CATAACTTTA GTGTGAGTTA CAGATGTAGA CAAAAGCAGG    2040

AGTATGAACA TTCAATCTGC ATCAATGGAA GATGGGATCC TGAACCAAAC TGTACAAGCA    2100

AAAGATTCTG CCCTCCTCCC CCGCAGATTC CAAATGCCCA AGTGATTGAA ACCACCGTGA    2160

AATACTTGGA TGGAGAAAAA GTATCTGTTC TTTGCCAAGA TGGTTACCTA ACTCAGGGCC    2220

CAGAAGAAAT GGTGTGTAAA CATGGAAGGT GGCAGTCGTT ACCACGCTGC ACGGAAAAAA    2280

TTCCATGTTC CCAGCCCCCT AAAATTGAAC ATGGATCTAT TAAGTCGCCC AGGTCCTCAG    2340

AAGAGAGGAG AGATTTAATT GAGTCCAGCA GTTATGAACA CGGAACTACA TTCAGCTATT    2400

GCTGTAGAGA TGGATTCAAG ATATCTGAAG AAAATAGGGT AACCTGCAAC ATGGGAAAAT    2460

GGAGCTCTCT GCCTCGTTGT GTTGGAATAC CTTGTGGACC CCCACCTTCA ATTCCTCTTG    2520

GTATTGTTTC TCATGAACTA GAAAGTTACC AATATGGAGA GGAGGTTACA TACAATTGTT    2580

CTGAAGGCTT TGGAATTGAT GGACCAGCAT TTATTAAATG TGTAGGAGGA CAGTGGTCTG    2640

AACCTCCCAA ATGCATAAAA ACTGATTGTG ACAACTTGCC CACATTTGAA ATTGCCAAAC    2700

CGACAGAAAA GAAAA    2715
```

(2) INFORMATION FOR SEQ ID NO: 4:

      (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 1532 base pairs
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: double
          (D) TOPOLOGY: unknown

      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```
TCGAGTCAAC TGCTCCCAGA TAGATCCAAG ACATGAGACT GTCAGCAAGA ATTATTTGGC    60

TTATATTATG GACTGTTTGT GTAGCAGAAG ATTGTAAAGG TCCTCCTCCA AGAGAAAATT    120

CAGAAATTCT CTCAGGTTCG TGGTCTGAAC AACTATATTC AGAAGGCACT CAGGCAACCT    180

ACAAATGCCG CCCTGGATAC CGAACACTTG GTACTATTGT AAAAGTATGC AAGAATGGAG    240
```

```
AATGGGTACC TTCTAACCCA TCAAGGATAT GTCGGAAAAG GCCATGTGGG CATCCCGGAG      300

ACACACCCTT TGGGTCCTTT AGGCTGGCAG TTGGATCTGA ATTTGAATTT GGTGCAAAGG      360

TTGTTTATAC ATGTGATGAA GGGTACCAAC TATTAGGTGA AATTGATTAC CGTTATCGAA      420

TGGATGGCTC TGACATTGTC ACATGTGTTA ATACGAAGTG GATTGGACAG CCGGTATGCA      480

AAGATAATTC CTGTGTGAAT CCACCACATG TGCCAAATGC TACTATACTA ACAAGGCACA      540

AGACTAAATA TCCATCTGGT GACAAAGTAC GTTATGACTG TAATAAACCT TTTGAATTAT      600

TTGGGGAAGT GGAAGTGATG TGCCAAAACG GGATTTGGAC AGAACCACCG AAATGCAAAG      660

ATTCAACAGG GAAATGTGGG CCTCCTCCAC CTATTGACAA TGGAGACATC ACCTCCTTGT      720

CATTACCAGT ATATGCACCA TTATCATCAG TTGAATATCA ATGCCAGAAC TATTATCTAC      780

TTAAGGGAAA TAAGATAGTA ACATGTAGAA ATGGAAAGTG GTCTCAGCCA CCAACCTGCT      840

TACATGCATG TGTGATACCA GAAGATATTA TGGAAAAACA TAATATAGTT CTCAGATGGA      900

GGGAAAATGC AAAGATTTAT TCCCAATCAG GGGAGAATAT TGAATTCATG TGTAAACCTG      960

GATATAGAAA ATTCAGAGGA TCACCTCCGT TTCGTACAAA GTGCATTGAG GGTCACATCA     1020

ATTATCCCAC TTGTGTATAA AATCGCTATA CAATTATTAG TAAACCTTAT GGATGAGAAA     1080

TGCACATGTA TATTACTAAT ACAGTTTGAA TTTACATTTA AATATTGTTT AGCTCATTTC     1140

CTCTAATAAG TATATAAACT TTTTTTATAT GGTGGTTAAT CAGTAACTTT ACAGACTGTT     1200

GCCACAAAGC AAGAACATTA CATTCAAAAC TCCTAATCCA AATATGATAT GTCCAAGGAC     1260

AAACTATGTC TAAGCAAGAA AATAAATGTT AGTTCTTCAA TGTCTGTTTT TATTCAGGAC     1320

CTTTCAGATT TTCTTGGATA CCTTTTGTTA GGTTCTGATT CACAGTGAGT GGAAGACACA     1380

CTGACTCTGA CTTCAAATTA GTATTACTTG CAATACATTA ACAACCAAAC TATCATAATA     1440

TCACAAATGT ATACAGCTAA TTACTGTGTC CTACCTTTGT ATCAATAAAG AAATCTAAGA     1500

AAGTTCTTGC TTAAAAAAAA AAAAAAAAAA AA                                   1532
```

(2) INFORMATION FOR SEQ ID NO: 5:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 27 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```
TTCAAGTAAC GTTAGAAGCT TAAGATG                                           27
```

(2) INFORMATION FOR SEQ ID NO: 6:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 33 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGCGGCCGCT CAAATCTTCT GAGATATAGG AGA   33

(2) INFORMATION FOR SEQ ID NO: 7:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 33 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGCGGCCGCT CATTTAATCC TTAAAGGTGA GTA   33

(2) INFORMATION FOR SEQ ID NO: 8:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 33 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGCGGCCGCT CATACTGGAA AGTATGGTCT ACG   33

(2) INFORMATION FOR SEQ ID NO: 9:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 207 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS:
            (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

        Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile Leu Thr
        1   5   10   15

        Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala Ile Tyr
                    20   25   30

```
Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met Val Cys
        35              40              45

Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys Gln Lys
    50              55              60

Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe Thr Leu
65          70              75                  80

Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr Thr Cys
                85              90              95

Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu Cys Asp
            100             105             110

Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val Lys Cys
        115             120             125

Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser Ala Met
    130             135             140

Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe Val Cys
145             150             155             160

Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys Ser Asp
            165             170             175

Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile Ser Cys
        180             185             190

Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys Ile
        195             200             205
```

(2) INFORMATION FOR SEQ ID NO: 10:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 265 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS:
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```
Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile Leu Thr
1               5               10              15

Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala Ile Tyr
            20              25              30

Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met Val Cys
        35              40              45

Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys Gln Lys
    50              55              60
```

```
Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe Thr Leu
65              70              75                      80

Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr Thr Cys
            85              90                      95

Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu Cys Asp
            100             105             110

Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val Lys Cys
        115             120             125

Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser Ala Met
    130             135             140

Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe Val Cys
145             150             155             160

Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys Ser Asp
            165             170             175

Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile Ser Cys
        180             185             190

Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys Ile Ile
        195             200             205

Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly Tyr Glu
    210             215             220

Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp Arg Pro
225             230             235             240

Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile Pro Asn
            245             250             255

Gly Asp Tyr Ser Pro Leu Arg Ile Lys
            260             265
```

(2) INFORMATION FOR SEQ ID NO: 11:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 329 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS:
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

```
Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile Leu Thr
1               5               10              15

Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala Ile Tyr
            20              25              30
```

```
Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met Val Cys
         35                  40                  45

Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys Gln Lys
         50                  55                  60

Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe Thr Leu
65                  70                  75                  80

Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr Thr Cys
                  85                  90                  95

Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu Cys Asp
              100                 105                 110

Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val Lys Cys
              115                 120                 125

Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser Ala Met
         130                 135                 140

Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe Val Cys
145                 150                 155                 160

Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys Ser Asp
                  165                 170                 175

Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile Ser Cys
              180                 185                 190

Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys Ile Ile
         195                 200                 205

Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly Tyr Glu
         210                 215                 220

Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp Arg Pro
225                 230                 235                 240

Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile Pro Asn
                  245                 250                 255

Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp Glu Ile
              260                 265                 270

Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly Asn Thr
         275                 280                 285

Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys Thr Leu
         290                 295                 300

Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr His Glu
305                 310                 315                 320

Asn Met Arg Arg Pro Tyr Phe Pro Val
              325
```

(2) INFORMATION FOR SEQ ID NO: 12:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 32 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CCTCCTCCTG GAAATGTTAG AAGCTTAAGA TG   32

(2) INFORMATION FOR SEQ ID NO: 13:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 29 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CCTCTAGATT ACTTGATACG GACGCATTT   29

(2) INFORMATION FOR SEQ ID NO: 14:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 428 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS:
        (D) TOPOLOGY: unknown

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile Leu Ser
1   5   10   15

Gly Ser Trp Ser Glu Gln Leu Tyr Ser Glu Gly Thr Gln Ala Thr Tyr
            20   25   30

Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys Val Cys
        35   40   45

Lys Asn Gly Glu Trp Val Pro Ser Asn Pro Ser Arg Ile Cys Arg Lys
    50   55   60

Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe Arg Leu
65   70   75   80

Ala Val Gly Ser Glu Phe Glu Phe Gly Ala Lys Val Val Tyr Thr Cys
                85   90   95

Asp Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu Cys Asp

```
                 100                    105                    110

Ala Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val Lys Cys
        115                 120                 125

Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly Ala Ala
        130                 135                 140

Glu Pro Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe Glu Cys
145                 150                 155                 160

Asn Ser Gly Phe Lys Ile Glu Gly Gln Lys Glu Met His Cys Ser Glu
                165                 170                 175

Asn Gly Leu Trp Ser Asn Glu Lys Pro Gln Cys Val Glu Ile Ser Cys
                180                 185                 190

Leu Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Tyr Leu Lys Pro Val
            195                 200                 205

Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Lys Gln Gly Phe Val
        210                 215                 220

Tyr Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp Asn Pro
225                 230                 235                 240

Gln Pro Ser Cys Glu Glu Met Thr Cys Leu Thr Pro Tyr Ile Pro Asn
                245                 250                 255

Gly Ile Tyr Thr Pro His Arg Ile Lys His Arg Ile Asp Asp Glu Ile
                260                 265                 270

Arg Tyr Glu Cys Lys Asn Gly Phe Tyr Pro Ala Thr Arg Ser Pro Val
            275                 280                 285

Ser Lys Cys Thr Ile Thr Gly Trp Ile Pro Ala Pro Arg Cys Ser Leu
        290                 295                 300

Lys Pro Cys Asp Phe Pro Gln Phe Lys His Gly Arg Leu Tyr Tyr Glu
305                 310                 315                 320

Glu Ser Arg Arg Pro Tyr Phe Pro Val Pro Ile Gly Lys Glu Tyr Ser
                325                 330                 335

Tyr Tyr Cys Asp Asn Gly Phe Thr Thr Pro Ser Gln Ser Tyr Trp Asp
            340                 345                 350

Tyr Leu Arg Cys Thr Val Asn Gly Trp Glu Pro Glu Val Pro Cys Leu
        355                 360                 365

Arg Gln Cys Ile Phe His Tyr Val Glu Tyr Gly Glu Ser Ser Tyr Trp
        370                 375                 380

Gln Arg Arg Tyr Ile Glu Gly Gln Ser Ala Lys Val Gln Cys His Ser
385                 390                 395                 400
```

```
Gly Tyr Ser Leu Pro Asn Gly Gln Asp Thr Tyr Tyr Cys Thr Glu Asn
                405                 410                 415

Gly Trp Ser Pro Pro Pro Lys Cys Val Arg Ile Lys
                420             425
```

CLAIMS

1. A molecule comprising at least complement control protein modules 1-4 of complement factor H, or a molecule resulting from partial modification thereof, or an allelic mutant thereof.

2. A molecule according to claim 1 comprising complement control protein modules 1-4, 1-5 or 1-6 of complement factor H, or a molecule resulting from partial modification thereof, or an allelic mutant thereof.

3. A molecule according to either one of claims 1 or 2, the complement factor H being human complement factor H.

4. A molecule according to claim 3, comprising complement control protein modules 1-4 and having the sequence of SEQ ID NO: 9.

5. A molecule according to claim 3, comprising complement control protein modules 1-5 and having the sequence of SEQ ID NO: 10.

6. A molecule according to claim 3, comprising complement control protein modules 1-6 and having the sequence of SEQ ID NO: 11.

7. A molecule according to either one of claims 1 or 2, the complement factor H being rat complement factor H.

8. A molecule according to claim 7, comprising complement control protein modules 1-7 and having the sequence of SEQ ID NO: 14.

9.   A molecule according to any one of claims 1-8, for use in inhibiting complement activation.

10.   A molecule according to claim 9, having an enhanced efficacy when compared to FHp155.

11.   The use of a molecule according to any one of the preceding claims in the manufacture of a medicament for inhibiting complement activation.

12.   A method of manufacture of a medicament for inhibiting complement activation, comprising the use of a molecule according to any one of claims 1-10.

13.   A method of inhibiting complement activation comprising the use of a molecule according to any one of claims 1-10.

14.   A nucleotide sequence having the formula of SEQ ID NO: 1 and encoding rat FH 4.3 kb mRNA.

15.   A nucleotide sequence having the formula of SEQ ID NO: 2 and encoding rat FH 1.0 mRNA.

16.   A DNA molecule comprising a sequence encoding a molecule according to any one of claims 1-10.

Figure 1

```
         10        20        30 -18   40        50        60
tcgagtcaactgctcccagatagatccaagacATGAGACTGTCAGCAAGAATTATTTGGC      rFH4.3
tcgagtcaactgctcccagatagatccaagacATGAGACTGTCAGCAAGAATTATTTGGC      rFH2.7
tcgagtcaactgctcccagatagatccaagacATGAGACTGTCAGCAAGAATTATTTGGC      rFH1.8
tcgagtcaactgctcccagatagatccaagacATGAGACTGTCAGCAAGAATTATTTGGC      rFH1.0


                                SCR1
         70        80       +1 90      100       110       120
TTATATTATGGACTGTTTGTGTAGCAGAAGATTGTAAAGGTCCTCCTCCAAGAGAAAATT      rFH4.3
TTATATTATGGACTGTTTGTGTAGCAGAAGATTGTAAAGGTCCTCCTCCAAGAGAAAATT      rFH2.7
TTATATTATGGACTGTTTGTGTAGCAGAAGATTGTAAAGGTCCTCCTCCAAGAGAAAATT      rFH1.8
TTATATTATGGACTGTTTGTGTAGCAGAAGATTGTAAAGGTCCTCCTCCAAGAGAAAATT      rFH1.0


         130       140       150       160       170       180
CAGAAATTCTCTCAGGTTCGTGGTCTGAACAACTATATTCAGAAGGCACTCAGGCAACCT      rFH4.3
CAGAAATTCTCTCAGGTTCGTGGTCTGAACAACTATATTCAGAAGGCACTCAGGCAACCT      rFH2.7
CAGAAATTCTCTCAGGTTCGTGGTCTGAACAACTATATTCAGAAGGCACTCAGGCAACCT      rFH1.8
CAGAAATTCTCTCAGGTTCGTGGTCTGAACAACTATATTCAGAAGGCACTCAGGCAACCT      rFH1.0


         190       200       210       220       230       240
ACAAATGCCGCCCTGGATACCGAACACTTGGTACTATTGTAAAAGTATGCAAGAATGGAG      rFH4.3
ACAAATGCCGCCCTGGATACCGAACACTTGGTACTATTGTAAAAGTATGCAAGAATGGAG      rFH2.7
ACAAATGCCGCCCTGGATACCGAACACTTGGTACTATTGTAAAAGTATGCAAGAATGGAG      rFH1.8
ACAAATGCCGCCCTGGATACCGAACACTTGGTACTATTGTAAAAGTATGCAAGAATGGAG      rFH1.0


                                SCR2a
         250       260       270       280       290       300
AATGGGTACCTTCTAACCCATCAAGGATATGTCGGAAAAGGCCATGTGGGCATCCCGGAG      rFH4.3
AATGGGTACCTTCTAACCCATCAAGGATATGTCGGAAAAGGCCATGTGGGCATCCCGGAG      rFH2.7
AATGGGTACCTTCTAACCCATCAAGGATATGTCGGAAAAGGCCATGTGGGCATCCCGGAG      rFH1.8
AATGGGTACCTTCTAACCCATCAAGGATATGTCGGAAAAGGCCATGTGGGCATCCCGGAG      rFH1.0


         310       320       330       340       350       360
ACACACCCTTTGGGTCCTTTAGGCTGGCAGTTGGATCTGAATTTGAATTTGGTGCAAAGG      rFH4.3
ACACACCCTTTGGGTCCTTTAGGCTGGCAGTTGGATCTGAATTTGAATTTGGTGCAAAGG      rFH2.7
ACACACCCTTTGGGTCCTTTAGGCTGGCAGTTGGATCTGAATTTGAATTTGGTGCAAAGG      rFH1.8
ACACACCCTTTGGGTCCTTTAGGCTGGCAGTTGGATCTGAATTTGAATTTGGTGCAAAGG      rFH1.0
```

```
                     SCR2b
        370       380       390       400       410       420
TTGTTTATACATGTGATGAAGGGTACCAACTATTAGGTGAAATTGATTACCGTGAATGTG   rFH4.3
TTGTTTATACATGTGATGAAGGGTACCAACTATTAGGTGAAATTGATTACCGTGAATGTG   rFH2.7
TTGTTTATACATGTGATGAAGGGTACCAACTATTAGGTGAAATTGATTACCGT-------   rFH1.8
TTGTTTATACATGTGATGAAGGGTACCAACTATTAGGTGAAATTGATTACCGTGAATGTG   rFH1.0


                             SCR3
        430       440       450       460       470       480
ATGCAGATGGGTGGACCAATGATATTCCAATATGTGAAGTTGTGAAGTGCTTGCCAGTGA   rFH4.3
ATGCAGATGGGTGGACCAATGATATTCCAATATGTGAAGTTGTGAAGTGCTTGCCAGTGA   rFH2.7
------------------------------------------------------------   rFH1.8
ATGCAGATGGGTGGACCAATGATATTCCAATATGTGAAGTTGTGAAGTGCTTGCCAGTGA   rFH1.0


        490       500       510       520       530       540
CAGAACTGGAGAATGGAAGAATTGTGAGTGGTGCAGCCGAACCAGACCAGGAATATTATT   rFH4.3
CAGAACTGGAGAATGGAAGAATTGTGAGTGGTGCAGCCGAACCAGACCAGGAATATTATT   rFH2.7
------------------------------------------------------------   rFH1.8
CAGAACTGGAGAATGGAAGAATTGTGAGTGGTGCAGCCGAACCAGACCAGGAATATTATT   rFH1.0


        550       560       570       580       590       600
TTGGACAGGTGGTACGCTTTGAATGCAACTCCGGCTTCAAGATTGAAGGACAGAAAGAAA   rFH4.3
TTGGACAGGTGGTACGCTTTGAATGCAACTCCGGCTTCAAGATTGAAGGACAGAAAGAAA   rFH2.7
------------------------------------------------------------   rFH1.8
TTGGACAGGTGGTACGCTTTGAATGCAACTCCGGCTTCAAGATTGAAGGACAGAAAGAAA   rFH1.0


                                             SCR4
        610       620       630       640       650       660
TGCACTGCTCATAAAATGGCCTCTGGAGCAATGAAAAGCCACAGTGTGTGGAAATTTCTT   rFH4.3
TGCACTGCTCATAAAATGGCCTCTGGAGCAATGAAAAGCCACAGTGTGTG----------   rFH2.7
------------------------------------------------------------   rFH1.8
TGCACTGCTCATAAAATGGCCTCTGGAGCAATGAAAAGCCACAGTGTGTGGAAATTTCTT   rFH1.0


        670       680       690       700       710       720
GCCTGCCACCACGAGTTGAAAATGGAGATGGTATATATCTGAAACCAGTTTACAAGGAGA   rFH4.3
------------------------------------------------------------   rFH2.7
------------------------------------------------------------   rFH1.8
GCCTGCCACCACGAGTTGAAAATGGAGAT-------------------------------   rFH1.0
```

```
           730       740       750       760       770       780
ATGAAAGATTCCAATATAAATGTAAGCAAGGTTTTGTGTACAAAGAAAGAGGGGATGCTG      rFH4.3
------------------------------------------------------------      rFH2.7
------------------------------------------------------------      rFH1.8
------------------------------------------------------------      rFH1.0


                                              SCR5
           790       800       810       820       830       840
TCTGCACGGGTTCTGGATGGAATCCTCAGCCTTCCTGTGAAGAAATGACATGTTTGACTC      rFH4.3
------------------------------------------------------------      rFH2.7
------------------------------------------------------------      rFH1.8
------------------------------------------------------------      rFH1.0


           850       860       870       880       890       900
CATATATTCCAAATGGTATCTACACACCTCACAGGATTAAACACAGAATTGATGATGAAA      rFH4.3
------------------------------------------------------------      rFH2.7
------------------------------------------------------------      rFH1.8
------------------------------------------------------------      rFH1.0


           910       920       930       940       950       960
TCAGATATGAATGTAAAAATGGCTTCTATCCTGCAACCCGATCACCTGTTTCAAAGTGTA      rFH4.3
------------------------------------------------------------      rFH2.7
------------------------------------------------------------      rFH1.8
------------------------------------------------------------      rFH1.0


                                     SCR6
           970       980       990      1000      1010      1020
CAATTACTGGCTGGATCCCTGCTCCAAGATGTAGCTTGAAACCTTGTGATTTTCCACAAT      rFH4.3
-----------------------------------TTGAAACCTTGTGATTTTCCACAAT      rFH2.7
------------------------------------------------------------      rFH1.8
------------------------------------------------------------      rFH1.0


          1030      1040      1050      1060      1070      1080
TCAAACATGGACGTCTGTATTATGAAGAAAGCCGGAGACCCTACTTCCCAGTACCTATAG      rFH4.3
TCAAACATGGACGTCTGTATTATGAAGAAAGCCGGAGACCCTACTTCCCAGTACCTATAG      rFH2.7
------------------------------------------------------------      rFH1.8
------------------------------------------------------------      rFH1.0
```

```
              1090      1100      1110      1120      1130      1140
GAAAGGAGTACAGCTATAACTGTGACAACGGGTTTACAACGCCTTCACAGTCATACTGGG      rFH4.3
GAAAGGAGTACAGCTATAACTGTGACAACGGGTTTACAACGCCTTCACAGTCATACTGGG      rFH2.7
-----------------------------------------------------------      rFH1.8
-----------------------------------------------------------      rFH1.0


                                                        SCR7
              1150      1160      1170      1180      1190      1200
ACTACCTTCGTTGCACAGTAAATGGGTGGGAGCCTGAAGTTCCATGCCTCAGGCAATGTA      rFH4.3
ACTACCTTCGTTGCACAGTAAATGGGTGGGAGCCTGAAGTTCCATGCCTCAGGCAATGTA      rFH2.7
-----------------------------------------------------------      rFH1.8
-----------------------------------------------------------      rFH1.0


              1210      1220      1230      1240      1250      1260
TTTTCCATTATGTGGAATATGGAGAATCTTCATACTGGCAAAGAAGATATATAGAGGGTC      rFH4.3
TTTTCCATTATGTGGAATATGGAGAATCTTCATACTGGCAAAGAAGATATATAGAGGGTC      rFH2.7
-----------------------------------------------------------      rFH1.8
-----------------------------------------------------------      rFH1.0


              1270      1280      1290      1300      1310      1320
AGTCTGCAAAAGTCCAGTGTCACAGTGGCTATAGTCTTCCAAATGGTCAAGATACATATT      rFH4.3
AGTCTGCAAAAGTCCAGTGTCACAGTGGCTATAGTCTTCCAAATGGTCAAGATACATATT      rFH2.7
-----------------------------------------------------------      rFH1.8
-----------------------------------------------------------      rFH1.0


                                                        SCR8
              1330      1340      1350      1360      1370      1380
ATTGTACAGAGAATGGCTGGTCCCCTCCTCCCAAATGCGTCCGTATCAAGACTTGTTCAG      rFH4.3
ATTGTACAGAGAATGGCTGGTCCCCTCCTCCCAAATGCGTCCGTATCAAGACTTGTTCAG      rFH2.7
-----------------------------------------------------------      rFH1.8
-----------------------------------------------------------      rFH1.0


              1390      1400      1410      1420      1430      1440
TATCAGATATAGAAATTGAAAATGGGTTTTTTTCTGAATCTGATTATACATATGCTCTAA      rFH4.3
TATCAGATATAGAAATTGAAAATGGGTTTTTTTCTGAATCTGATTATACATATGCTCTAA      rFH2.7
-----------------------------------------------------------      rFH1.8
-----------------------------------------------------------      rFH1.0
```

```
       1450      1460      1470      1480      1490      1500
ATAGAAAAACACGGTATAGATGTAAACAGGGATATGTAACAAATACCGGAGAAATATCAG    rFH4.3
ATAGAAAAACACGGTATAGATGTAAACAGGGATATGTAACAAATACCGGAGAAATATCAG    rFH2.7
------------------------------------------------------------    rFH1.8
                                                                rFH1.0


                                                        SCR9
       1510      1520      1530      1540      1550      1560
GAATAATTACTTGTCTTCAAGATGGATGGTCACCTCGACCCTCATGCATTAAGTCTTGTG    rFH4.3
GAATAATTACTTGTCTTCAAGATGGATGGTCACCTCGACCCTCATGCATTAAGTCTTGTG    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


       1570      1580      1590      1600      1610      1620
ATATGCCTGTATTTGAGAATTCTATGACTAAGAATAATAACACATGGTTTAAACTCAATG    rFH4.3
ATATGCCTGTATTTGAGAATTCTATGACTAAGAATAATAACACATGGTTTAAACTCAATG    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


       1630      1640      1650      1660      1670      1680
ACAAATTAGACTATGAATGTCACATTGGATATGAAAATGAATATAAACATACCAAAGGCT    rFH4.3
ACAAATTAGACTATGAATGTCACATTGGATATGAAAATGAATATAAACATACCAAAGGCT    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


                                                        SCR10
       1690      1700      1710      1720      1730      1740
CTATAACATGTACTTATGATGGATGGTCTAGTACACCCTCCTGTTATGAAAGAGAATGCA    rFH4.3
CTATAACATGTACTTATGATGGATGGTCTAGTACACCCTCCTGTTATGAAAGAGAATGCA    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


       1750      1760      1770      1780      1790      1800
GCATTCCCCTGTTACACCAAGACTTAGTTGTTTTTCCCAGAGAAGTAAAATACAAAGTTG    rFH4.3
GCATTCCCCTGTTACACCAAGACTTAGTTGTTTTTCCCAGAGAAGTAAAATACAAAGTTG    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
                  1810      1820      1830      1840      1850      1860
GAGATTCGTTGAGTTTCTCTTGCCGTTCAGGACACAGAGTTGGAGCAGATTTAGTGCAAT    rFH4.3
GAGATTCGTTGAGTTTCTCTTGCCGTTCAGGACACAGAGTTGGAGCAGATTTAGTGCAAT    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
                                                        SCR11
                  1870      1880      1890      1900      1910      1920
GCTACCACTTTGGATGGTCCCCTAATTTCCCAACGTGTGAAGGCCAAGTAAAATCATGTG    rFH4.3
GCTACCACTTTGGATGGTCCCCTAATTTCCCAACGTGTGAAGGCCAAGTAAAATCATGTG    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
                  1930      1940      1950      1960      1970      1980
ACCAACCTCTTGAAATCCCGAATGGGGAAATAAAGGGAACAAAAAAAGTTGAATACAGCC    rFH4.3
ACCAACCTCTTGAAATCCCGAATGGGGAAATAAAGGGAACAAAAAAAGTTGAATACAGCC    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
                  1990      2000      2010      2020      2030      2040
ATGGTGACGTGGTGGAATATGATTGCAAACCTAGATTTCTACTGAAGGGACCCAATAAAA    rFH4.3
ATGGTGACGTGGTGGAATATGATTGCAAACCTAGATTTCTACTGAAGGGACCCAATAAAA    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
                                                        SCR12
                  2050      2060      2070      2080      2090      2100
TCCAGTGTGTTGACGGGAAGTGGACAAGGTTGCCGATATGCGTTGAGTATGAGAGAACAT    rFH4.3
TCCAGTGTGTTGACGGGAAGTGGACAAGGTTGCCGATATGCGTTGAGTATGAGAGAACAT    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
                  2110      2120      2130      2140      2150      2160
GTGGAGACCTTCCTGAACTTGAGCATGGCTCTGTCAAGTTATCTGTCCCTCCCTACCATC    rFH4.3
GTGGAGACCTTCCTGAACTTGAGCATGGCTCTGTCAAGTTATCTGTCCCTCCCTACCATC    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
            2170      2180      2190      2200      2210      2220
        ATGGAGATTCAGTGGAGTTCACTTGTACAGAAACCTTCACAATGATTGGACATGCAGTAG    rFH4.3
        ATGGAGATTCAGTGGAGTTCACTTGTACAGAAACCTTCACAATGATTGGACATGCAGTAG    rFH2.7
        ------------------------------------------------------------    rFH1.8
        ------------------------------------------------------------    rFH1.0
```

```
                                                      SCR13
            2230      2240      2250      2260      2270      2280
        TTTTCTGCATTAGTGGAAGGTGGACCGAGCTTCCTCAATGTGTTGCAACAGATCAACTGG    rFH4.3
        TTTTCTGCATTAGTGGAAGGTGGACCGAGCTTCCTCAATGTGTTGCAACAGATCAACTGG    rFH2.7
        ------------------------------------------------------------    rFH1.8
        ------------------------------------------------------------    rFH1.0
```

```
            2290      2300      2310      2320      2330      2340
        AGAAGTGTAAAGCCCCGAAGTCAACTGGCATAGATGCAATTCATCCAAATAAGAATGAAT    rFH4.3
        AGAAGTGTAAAGCCCCGAAGTCAACTGGCATAGATGCAATTCATCCAAATAAGAATGAAT    rFH2.7
        ------------------------------------------------------------    rFH1.8
                                                                        rFH1.0
```

```
            2350      2360      2370      2380      2390      2400
        TTAATCATAACTTTAGTGTGAGTTACAGATGTAGACAAAAGCAGGAGTATGAACATTCAA    rFH4.3
        TTAATCATAACTTTAGTGTGAGTTACAGATGTAGACAAAAGCAGGAGTATGAACATTCAA    rFH2.7
        ------------------------------------------------------------    rFH1.8
        ------------------------------------------------------------    rFH1.0
```

```
                                            SCR14
            2410      2420      2430      2440      2450      2460
        TCTGCATCAATGGAAGATGGGATCCTGAACCAAACTGTACAAGCAAAAGATTCTGCCCTC    rFH4.3
        TCTGCATCAATGGAAGATGGGATCCTGAACCAAACTGTACAAGCAAAAGATTCTGCCCTC    rFH2.7
        ------------------------------------------------------------    rFH1.8
        ------------------------------------------------------------    rFH1.0
```

```
            2470      2480      2490      2500      2510      2520
        CTCCCCCGCAGATTCCAAATGCCCAAGTGATTGAAACCACCGTGAAATACTTGGATGGAG    rFH4.3
        CTCCCCCGCAGATTCCAAATGCCCAAGTGATTGAAACCACCGTGAAATACTTGGATGGAG    rFH2.7
        ------------------------------------------------------------    rFH1.8
        ------------------------------------------------------------    rFH1.0
```

```
            2530      2540      2550      2560      2570      2580
AAAAAGTATCTGTTCTTTGCCAAGATGGTTACCTAACTCAGGGCCCAGAAGAAATGGTGT    rFH1.8
AAAAAGTATCTGTTCTTTGCCAAGATGGTTACCTAACTCAGGGCCCAGAAGAAATGGTGT    rFH2.7
-----------------------------------------------------------    rFH4.3
-----------------------------------------------------------    rFH1.0
```

```
                                                   SCR15
            2590      2600      2610      2620      2630      2640
GTAAACATGGAAGGTGGCAGTCGTTACCACGCTGCACGGAAAAAATTCCATGTTCCCAGC    rFH4.3
GTAAACATGGAAGGTGGCAGTCGTTACCACGCTGCACGGAAAAAATTCCATGTTCCCAGC    rFH2.7
-----------------------------------------------------------    rFH1.8
-----------------------------------------------------------    rFH1.0
```

```
            2650      2660      2670      2680      2690      2700
CCCCTAAAATTGAACATGGATCTATTAAGTCGCCCAGGTCCTCAGAAGAGAGGAGAGATT    rFH4.3
CCCCTAAAATTGAACATGGATCTATTAAGTCGCCCAGGTCCTCAGAAGAGAGGAGAGATT    rFH2.7
-----------------------------------------------------------    rFH1.8
-----------------------------------------------------------    rFH1.0
```

```
            2710      2720      2730      2740      2750      2760
TAATTGAGTCCAGCAGTTATGAACACGGAACTACATTCAGCTATTGCTGTAGAGATGGAT    rFH4.3
TAATTGAGTCCAGCAGTTATGAACACGGAACTACATTCAGCTATTGCTGTAGAGATGGAT    rFH2.7
-----------------------------------------------------------    rFH1.8
-----------------------------------------------------------    rFH1.0
```

```
            2770      2780      2790      2800      2810      2820
TCAAGATATCTGAAGAAAATAGGGTAACCTGCAACATGGGAAAATGGAGCTCTCTGCCTC    rFH4.3
TCAAGATATCTGAAGAAAATAGGGTAACCTGCAACATGGGAAAATGGAGCTCTCTGCCTC    rFH2.7
-----------------------------------------------------------    rFH1.8
-----------------------------------------------------------    rFH1.0
```

```
       SCR16
            2830      2840      2850      2860      2870      2880
GTTGTGTTGGAATACCTTGTGGACCCCCACCTTCAATTCCTCTTGGTATTGTTTCTCATG    rFH4.3
GTTGTGTTGGAATACCTTGTGGACCCCCACCTTCAATTCCTCTTGGTATTGTTTCTCATG    rFH2.7
-----------------------------------------------------------    rFH1.8
-----------------------------------------------------------    rFH1.0
```

```
               2890      2900      2910      2920      2930      2940
AACTAGAAAGTTACCAATATGGAGAGGAGGTTACATACAATTGTTCTGAAGGCTTTGGAA    rFH4.3
AACTAGAAAGTTACCAATATGGAGAGGAGGTTACATACAATTGTTCTGAAGGCTTTGGAA    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


               2950      2960      2970      2980      2990      3000
TTGATGGACCAGCATTTATTAAATGTGTAGGAGGACAGTGGTCTGAACCTCCCAAATGCA    rFH4.3
TTGATGGACCAGCATTTATTAAATGTGTAGGAGGACAGTGGTCTGAACCTCCCAAATGCA    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


   SCR17
               3010      3020      3030      3040      3050      3060
TAAAAACTGATTGTGACAACTTGCCCACATTTGAAATTGCCAAACCGACAGAAAAGAAAA    rFH4.3
TAAAAACTGATTGTGACAACTTGCCCACATTTGAAATTGCCAAACCGACAGAAAAGAAAA    rFH2.7
------------------------------------------------------------    rFH1.8
------------------------------------------------------------    rFH1.0


               3070      3080      3090      3100      3110      3120
AAAAATCATACAGGTCAGGAGAACAAGTGACATTCAGATGTCCACCTCCGTATCGAATGG    rFH4.3
------------------------------------------------------------    rFH2.7
---------------------------------------------------TATCGAATGG    rFH1.8
------------------------------------------------------------    rFH1.0


               3130      3140      3150      3160      3170      3180
ATGGCTCTGACATTGTCACATGTGTTAATACGAAGTGGATTGGACAGCCGGTATGCAAAG    rFH4.3
------------------------------------------------------------    rFH2.7
ATGGCTCTGACATTGTCACATGTGTTAATACGAAGTGGATTGGACAGCCGGTATGCAAAG    rFH1.8
------------------------------------------------------------    rFH1.0


   SCR18
               3190      3200      3210      3220   3223   3240
ATAATTCCTGTGTGAATCCACCACATGTGCCAAATGCTACTATACTAACAAGGCACAAGA    rFH4.3
------------------------------------------------------------    rFH2.7
ATAATTCCTGTGTGAATCCACCACATGTGCCAAATGCTACTATACTAACAAGGCACAAGA    rFH1.8
------------------------------------------------------------    rFH1.0
```

```
        3250      3260      3270      3280      3290      3300
CTAAATATCCATCTGGTGACAAAGTACGTTATGACTGTAATAAACCTTTTGAATTATTTG     rFH4.3
------------------------------------------------------------     rFH2.7
CTAAATATCCATCTGGTGACAAAGTACGTTATGACTGTAATAAACCTTTTGAATTATTTG     rFH1.8
------------------------------------------------------------     rFH1.0
```

```
        3310      3320      3330      3340      3350      3360
GGGAAGTGGAAGTGATGTGCCAAAACGGGATTTGGACAGAACCACCGAAATGCAAAGATT     rFH4.3
------------------------------------------------------------     rFH2.7
GGGAAGTGGAAGTGATGTGCCAAAACGGGATTTGGACAGAACCACCGAAATGCAAAGATT     rFH1.8
------------------------------------------------------------     rFH1.0
```

```
    SCR19
        3370      3380      3390      3400      3410      3420
CAACAGGGAAATGTGGGCCTCCTCCACCTATTGACAATGGAGACATCACCTCCTTGTCAT     rFH4.3
------------------------------------------------------------     rFH2.7
CAACAGGGAAATGTGGGCCTCCTCCACCTATTGACAATGGAGACATCACCTCCTTGTCAT     rFH1.8
------------------------------------------------------------     rFH1.0
```

```
        3430      3440      3450      3460      3470      3480
TACCAGTATATGCACCATTATCATCAGTTGAATATCAATGCCAGAACTATTATCTACTTA     rFH4.3
------------------------------------------------------------     rFH2.7
TACCAGTATATGCACCATTATCATCAGTTGAATATCAATGCCAGAACTATTATCTACTTA     rFH1.8
------------------------------------------------------------     rFH1.0
```

```
        3490      3500      3510      3520      3530      3540
AGGGAAATAAGATAGTAACATGTAGAAATGGAAAGTGGTCTCAGCCACCAACCTGCTTAC     rFH4.3
------------------------------------------------------------     rFH2.7
AGGGAAATAAGATAGTAACATGTAGAAATGGAAAGTGGTCTCAGCCACCAACCTGCTTAC     rFH1.8
------------------------------------------------------------     rFH1.0
```

```
    SCR20
        3550      3560      3570      3580      3590      3600
ATGCATGTGTGATACCAGAAGATATTATGGAAAAACATAATATAGTTCTCAGATGGAGGG     rFH4.3
------------------------------------------------------------     rFH2.7
ATGCATGTGTGATACCAGAAGATATTATGGAAAAACATAATATAGTTCTCAGATGGAGGG     rFH1.8
------------------------------------------------------------     rFH1.0
```

```
          3610      3620      3630      3640      3650      3660
AAAATGCAAAGATTTATTCCCAATCAGGGGAGAATATTGAATTCATGTGTAAACCTGGAT    rFH4.3
-----------------------------------------------------------    rFH2.7
AAAATGCAAAGATTTATTCCCAATCAGGGGAGAATATTGAATTCATGTGTAAACCTGGAT    rFH1.8
--------------------------------------------------------GGAT    rFH1.0


          3670      3680      3690      3700      3710      3720
ATAGAAAATTCAGAGGATCACCTCCGTTTCGTACAAAGTGCATTGAGGGTCACATCAATT    rFH4.3
-----------------------------------------------------------    rFH2.7
ATAGAAAATTCAGAGGATCACCTCCGTTTCGTACAAAGTGCATTGAGGGTCACATCAATT    rFH1.8
ATAGAAAATTCAGAGGATCACCTCCGTTTCGTACAAAGTGCATTGAGGGTCACATCAATT    rFH1.0


          3730      3740      3750      3760      3770      3780
ATCCCACTTGTGTATAAaatcgctatacaattattagtaaaccttatggatgagaaatgc    rFH4.3
-----------------------------------------------------------    rFH2.7
ATCCCACTTGTGTATAAaatcgctatacaattattagtaaaccttatggatgagaaatgc    rFH1.8
ATCCCACTTGTGTATAAaatcgctatacaattattagtaaaccttatggatgacactttg    rFH1.0


          3790      3800      3810      3820      3830      3840
acatgtatattactaatacagtttgaatttacatttaaatattgtttagctcatttcctc    rFH4.3
-----------------------------------------------------------    rFH2.7
acatgtatattactaatacagtttgaatttacatttaaatattgtttagctcatttcctc    rFH1.8
tttagaaatgcacatgtatattactaatacagtttgaatttacatttgaaaaa-------    rFH1.0


          3850      3860      3870      3880      3890      3900
taataagtatataaactttttttatatggtggttaatcagtaactttacagactgttgcc    rFH4.3
-----------------------------------------------------------    rFH2.7
taataagtatataaactttttttatatggtggttaatcagtaactttacagactgttgcc    rFH1.8
-----------------------------------------------------------    rFH1.0
```

```
            3910      3920      3930      3940      3950      3960
      acaaagcaagaacattacattcaaaactcctaatccaaatatgatatgtccaaggacaaa    rFH4.3
      -----------------------------------------------------------    rFH2.7
      acaaagcaagaacattacattcaaaactcctaatccaaatatgatatgtccaaggacaaa    rFH1.8
      -----------------------------------------------------------    rFH1.0



            3970      3980      3990      4000      4010      4020
      ctatgtctaagcaagaaaataaatgttagttcttcaatgtctgtttttattcaggacctt    rFH4.3
      -----------------------------------------------------------    rFH2.7
      ctatgtctaagcaagaaaataaatgttagttcttcaatgtctgtttttattcaggacctt    rFH1.8
      -----------------------------------------------------------    rFH1.0



            4030      4040      4050      4060      4070      4080
      tcagattttcttggataccttttgttaggttctgattcacagtgagtggaagacacactg    rFH4.3
      -----------------------------------------------------------    rFH2.7
      tcagattttcttggataccttttgttaggttctgattcacagtgagtggaagacacactg    rFH1.8
      -----------------------------------------------------------    rFH1.0



            4090      4100      4110      4120      4130      4140
      actctgacttcaaattagtattacttgcaatacattaacaaccaaactatcataatatca    rFH4.3
      -----------------------------------------------------------    rFH2.7
      actctgacttcaaattagtattacttgcaatacattaacaaccaaactatcataatatca    rFH1.8
      -----------------------------------------------------------    rFH1.0



            4150      4160      4170      4180      4190      4200
      caaatgtatacagctaattactgtgtcctacctttgtatcaataaagaaatctaagaaag    rFH4.3
      -----------------------------------------------------------    rFH2.7
      caaatgtatacagctaattactgtgtcctacctttgtatcaataaagaaatctaagaaag    rFH1.8
      -----------------------------------------------------------    rFH1.0



            4210      4220      4230
      ttcttgcttaaaaaaaaaaaaaaaaaaaaa                                 rFH4.3
      -----------------------------                                  rFH2.7
      ttcttgcttaaaaaaaaaaaaaaaaaaaaa                                 rFH1.8
      -----------------------------                                  rFH1.0
```

Figure 2

Figure 3

Figure 4

	FH SCR1-4	FH SCR1-5	FH SCR1-6	FHp155
10 nM	34 ± 2.3	36 ± 3.2	35 ± 1.3	1.6 ± 0.7
100 nM	144 ± 9	148 ± 7	156 ± 11	4.2 ± 1.6
200 nM	363 ± 14	374 ± 18	383 ± 11	7.8 ± 1.3